Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform? | Zendy

Roger L. Nation | Zendy; Samira M. Garonzik | Zendy; Jian Li | Zendy; Visanu Thamlikitkul | Zendy; Evangelos J. GiamarellosBourboulis | Zendy; David L. Paterson | Zendy; John Turnidge | Zendy; Alan Forrest | Zendy; Fernanda P. Silveira | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?

Author(s) -

Roger L. Nation,

Samira M. Garonzik,

Jian Li,

Visanu Thamlikitkul,

Evangelos J. GiamarellosBourboulis,

David L. Paterson,

John Turnidge,

Alan Forrest,

Fernanda P. Silveira

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ964

Subject(s) - medicine , colistin , food and drug administration , intensive care medicine , drug , pharmacology , antibiotics , microbiology and biotechnology , biology

The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved updated dose recommendations for intravenous colistin in patients with various degrees of renal function. We assessed the recommendations in relation to their ability to achieve clinically relevant plasma colistin concentrations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research